Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study

Table 1 Expected progression free survival and applied regimen in the current study

	1st line chemotherapy		2nd line chemotherapy
Cancer site	Regimen (reference)	Expected PFS [months]	Regimen (reference)	Expected PFS [months]
Colon/rectum	FOLFOX + bevacizumab or cetuximab [34, 35]	9	FOLFIRI+/− panitumumab or bevacizumab [36–38]	5
Pancreas	Gemcitabine based [39, 40]	4	fluoropyridimine +/− oxaliplatin [41]	2
Stomach/esophagus	fluoropyrimidine/platinum +/− trastuzumab for HER2 positive [42–44]	6	taxane or irinotecan [45]	3
Anal	5FU/platinum [46]	6	-	-
Cholangiocarcinoma	Gemcitabine +/− Cisplatin [47]	6	-	-

ISSN: 1472-684X